eGROSS pro-x – Ergonomic, mobile grossing work centre
This all-in-one grossing workstation has been specifically designed to integrate state of the art tools and standardization into a 21st century system for gross
Molecular diagnostics are rapidly becoming part of the standard of care for cancer patients. This biomarker based approach serves to select patients likely to benefit from targeted treatment regimens and potentially assists in their inclusion into appropriate clinical trials.
Pathology is an “image-based” discipline, where interpretation uses both visual and non-visual data. As time becomes more and more valuable, a systematic approach to descriptions at the grossing station is essential in maximizing user efficiency.
LEF-1 and SOX-11 (MRQ-58) and – top IHC performers for your Lymphoma panel.
We are pleased to be launching the next edition of Cell Marque disease of the month. This is a continuation of a series of disease overviews where we will present commonly diagnosed disease groups and the relevant Cell Marque immunohistochemistry antibodies to assist in the disease diagnosis.
p16INK4A (also known as 16P04) IHC is the most common test run on cervical biopsies to determine the presence of cervical intraepithelial neoplasms (CIN) caused by HPV
Cell Marque™ Tissue Diagnostics SDHB (EP288) is now available. Succinate dehydrogenase B (SDHB) is a useful antibody for subtyping Gastrointestinal stromal tumours (GIST).
A recent publication in the oncology field revealed that high blood levels of soluble OX40 indicate reduced survival in patients with advanced colorectal cancer (CRC).
Often limited attention is given to bone fixation and decalcification and bone samples are, at times, abandoned in a jar and immersed in a decalcification solution of unknown composition.
Breast cancer is the most common cancer affecting women in Australia and New Zealand1 and the second most commonly diagnosed cancer in Australia2.